

Lizzia Raffaghello

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8309473/publications.pdf>

Version: 2024-02-01

94
papers

7,024
citations

66343

42
h-index

60623

81
g-index

96
all docs

96
docs citations

96
times ranked

10470
citing authors

#	ARTICLE	IF	CITATIONS
1	Increased Level of Extracellular ATP at Tumor Sites: In Vivo Imaging with Plasma Membrane Luciferase. PLoS ONE, 2008, 3, e2599.	2.5	546
2	Fasting Cycles Retard Growth of Tumors and Sensitize a Range of Cancer Cell Types to Chemotherapy. Science Translational Medicine, 2012, 4, 124ra27.	12.4	531
3	Starvation-dependent differential stress resistance protects normal but not cancer cells against high-dose chemotherapy. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 8215-8220.	7.1	471
4	Human Mesenchymal Stem Cells Inhibit Neutrophil Apoptosis: A Model for Neutrophil Preservation in the Bone Marrow Niche. Stem Cells, 2008, 26, 151-162.	3.2	442
5	Expression of P2X7 Receptor Increases <i>In Vivo</i> Tumor Growth. Cancer Research, 2012, 72, 2957-2969.	0.9	324
6	Reduced Levels of IGF-I Mediate Differential Protection of Normal and Cancer Cells in Response to Fasting and Improve Chemotherapeutic Index. Cancer Research, 2010, 70, 1564-1572.	0.9	245
7	Dysregulated metabolism contributes to oncogenesis. Seminars in Cancer Biology, 2015, 35, S129-S150.	9.6	225
8	Designing a broad-spectrum integrative approach for cancer prevention and treatment. Seminars in Cancer Biology, 2015, 35, S276-S304.	9.6	220
9	Downregulation and/or Release of NKG2D Ligands as Immune Evasion Strategy of Human Neuroblastoma. Neoplasia, 2004, 6, 558-568.	5.3	216
10	Accelerated Tumor Progression in Mice Lacking the ATP Receptor P2X7. Cancer Research, 2015, 75, 635-644.	0.9	157
11	The P2X7 receptor is a key modulator of the PI3K/GSK3 β /VEGF signaling network: evidence in experimental neuroblastoma. Oncogene, 2015, 34, 5240-5251.	5.9	149
12	Use of luciferase probes to measure ATP in living cells and animals. Nature Protocols, 2017, 12, 1542-1562.	12.0	149
13	The P2X7 Receptor Sustains the Growth of Human Neuroblastoma Cells through a Substance P-Dependent Mechanism. Cancer Research, 2006, 66, 907-914.	0.9	137
14	Immunogenicity of Human Mesenchymal Stem Cells in HLA-Class I-Restricted T-Cell Responses Against Viral or Tumor-Associated Antigens. Stem Cells, 2008, 26, 1275-1287.	3.2	134
15	Fasting induces anti-Warburg effect that increases respiration but reduces ATP-synthesis to promote apoptosis in colon cancer models. Oncotarget, 2015, 6, 11806-11819.	1.8	127
16	Proteome Profiling of Neuroblastoma-Derived Exosomes Reveal the Expression of Proteins Potentially Involved in Tumor Progression. PLoS ONE, 2013, 8, e75054.	2.5	122
17	Systemic and Intraplaque Mediators of Inflammation Are Increased in Patients Symptomatic for Ischemic Stroke. Stroke, 2010, 41, 1394-1404.	2.0	106
18	Fasting and differential chemotherapy protection in patients. Cell Cycle, 2010, 9, 4474-4476.	2.6	102

#	ARTICLE	IF	CITATIONS
19	ATP/P2X7 axis modulates myeloid-derived suppressor cell functions in neuroblastoma microenvironment. <i>Cell Death and Disease</i> , 2014, 5, e1135-e1135.	6.3	102
20	Human Neuroblastoma Cells Trigger an Immunosuppressive Program in Monocytes by Stimulating Soluble HLA-G Release. <i>Cancer Research</i> , 2007, 67, 6433-6441.	0.9	100
21	Delivery of c-myc Antisense Oligodeoxynucleotides to Human Neuroblastoma Cells Via Disialoganglioside GD2-Targeted Immunoliposomes: Antitumor Effects. <i>Journal of the National Cancer Institute</i> , 2000, 92, 253-261.	6.3	98
22	Multiple defects of the antigen-processing machinery components in human neuroblastoma: immunotherapeutic implications. <i>Oncogene</i> , 2005, 24, 4634-4644.	5.9	92
23	Bevacizumab-mediated tumor vasculature remodelling improves tumor infiltration and antitumor efficacy of GD2-CAR T cells in a human neuroblastoma preclinical model. <i>Oncoimmunology</i> , 2018, 7, e1378843.	4.6	88
24	Mechanisms of immune evasion of human neuroblastoma. <i>Cancer Letters</i> , 2005, 228, 155-161.	7.2	76
25	Mechanisms of BSO (L-buthionine-S,R-sulfoximine)-induced cytotoxic effects in neuroblastoma. <i>Free Radical Biology and Medicine</i> , 2008, 44, 474-482.	2.9	70
26	Neuroblastic tumors associated with opsoclonus-myoclonus syndrome: histological, immunohistochemical and molecular features of 15 Italian cases. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2003, 442, 555-562.	2.8	68
27	Synergistic Interactions between HDAC and Sirtuin Inhibitors in Human Leukemia Cells. <i>PLoS ONE</i> , 2011, 6, e22739.	2.5	68
28	Discovery of a novel glucose metabolism in cancer: The role of endoplasmic reticulum beyond glycolysis and pentose phosphate shunt. <i>Scientific Reports</i> , 2016, 6, 25092.	3.3	67
29	Oct-4+/Tenascin C+ neuroblastoma cells serve as progenitors of tumor-derived endothelial cells. <i>Cell Research</i> , 2011, 21, 1470-1486.	12.0	66
30	CCL19 and CXCL12 Trigger in Vitro Chemotaxis of Human Mantle Cell Lymphoma B Cells. <i>Clinical Cancer Research</i> , 2004, 10, 964-971.	7.0	64
31	Inhibition of neuroblastoma-induced angiogenesis by fenretinide. <i>International Journal of Cancer</i> , 2001, 94, 314-321.	5.1	63
32	Immunosuppressive Microenvironment in Neuroblastoma. <i>Frontiers in Oncology</i> , 2013, 3, 167.	2.8	61
33	Mesenchymal stromal cells and autoimmunity. <i>International Immunology</i> , 2017, 29, 49-58.	4.0	61
34	GD2-mediated melanoma cell targeting and cytotoxicity of liposome-entrapped fenretinide. , 1999, 81, 268-274.		57
35	Antitumor effect of combined NAMPT and CD73 inhibition in an ovarian cancer model. <i>Oncotarget</i> , 2016, 7, 2968-2984.	1.8	57
36	Immunological mechanisms in opsoclonus-myoclonus associated neuroblastoma. <i>European Journal of Paediatric Neurology</i> , 2009, 13, 219-223.	1.6	54

#	ARTICLE	IF	CITATIONS
37	In vivo angiogenic activity of neuroblastoma correlates with MYCN oncogene overexpression. International Journal of Cancer, 2002, 102, 351-354.	5.1	52
38	Starvation, detoxification, and multidrug resistance in cancer therapy. Drug Resistance Updates, 2012, 15, 114-122.	14.4	52
39	Immunogenicity of Human Neuroblastoma. Annals of the New York Academy of Sciences, 2004, 1028, 69-80.	3.8	48
40	CXCL12 Does Not Attract CXCR4+ Human Metastatic Neuroblastoma Cells: Clinical Implications. Clinical Cancer Research, 2006, 12, 77-82.	7.0	47
41	Mechanisms of the Antitumor Activity of Human V β 9V α 2 T Cells in Combination With Zoledronic Acid in a Preclinical Model of Neuroblastoma. Molecular Therapy, 2013, 21, 1034-1043.	8.2	47
42	Cancer associated fibroblasts in hematological malignancies. Oncotarget, 2015, 6, 2589-2603.	1.8	46
43	Structure-activity relationships of novel substituted naphthalene diimides as anticancer agents. European Journal of Medicinal Chemistry, 2012, 57, 417-428.	5.5	44
44	Divergent targets of glycolysis and oxidative phosphorylation result in additive effects of metformin and starvation in colon and breast cancer. Scientific Reports, 2016, 6, 19569.	3.3	43
45	A Novel Mechanism of Soluble HLA-G Mediated Immune Modulation: Downregulation of T Cell Chemokine Receptor Expression and Impairment of Chemotaxis. PLoS ONE, 2010, 5, e11763.	2.5	43
46	In vitro and in vivo antitumor activity of liposomal fenretinide targeted to human neuroblastoma. International Journal of Cancer, 2003, 104, 559-567.	5.1	41
47	CX3CR1 Is Expressed by Human B Lymphocytes and Mediates CX3CL1 Driven Chemotaxis of Tonsil Centrocytes. PLoS ONE, 2009, 4, e8485.	2.5	40
48	Anti-GD2 monoclonal antibody immunotherapy: a promising strategy in the prevention of neuroblastoma relapse. Cancer Letters, 2003, 197, 205-209.	7.2	37
49	Curcumin induces a fatal energetic impairment in tumor cells in vitro and in vivo by inhibiting ATP-synthase activity. Carcinogenesis, 2018, 39, 1141-1150.	2.8	37
50	Immunoliposomal fenretinide: a novel antitumoral drug for human neuroblastoma. Cancer Letters, 2003, 197, 151-155.	7.2	36
51	Grb7 Upregulation Is a Molecular Adaptation to HER2 Signaling Inhibition Due to Removal of Akt-Mediated Gene Repression. PLoS ONE, 2010, 5, e9024.	2.5	35
52	Classification and biology of tumour associated stromal cells. Immunology Letters, 2015, 168, 175-182.	2.5	34
53	Mechanisms of free-radical induction in relation to fenretinide-induced apoptosis of neuroblastoma. Journal of Cellular Biochemistry, 2003, 89, 698-708.	2.6	33
54	Expression and Functional Analysis of Human Leukocyte Antigen Class I Antigen-Processing Machinery in Medulloblastoma. Cancer Research, 2007, 67, 5471-5478.	0.9	33

#	ARTICLE	IF	CITATIONS
55	Potential of mesenchymal stem cells for the therapy of autoimmune diseases. Expert Review of Clinical Immunology, 2010, 6, 211-218.	3.0	33
56	Heterogeneous Expression of Interleukin-18 and Its Receptor in B-Cell Lymphoproliferative Disorders Deriving from Naive, Germinal Center, and Memory B Lymphocytes. Clinical Cancer Research, 2004, 10, 144-154.	7.0	32
57	Expression of costimulatory molecules in human neuroblastoma. Evidence that CD40+ neuroblastoma cells undergo apoptosis following interaction with CD40L. British Journal of Cancer, 2003, 88, 1527-1536.	6.4	31
58	N-(4-hydroxyphenyl) retinamide is cytotoxic to melanoma cells in vitro through induction of programmed cell death. , 1999, 81, 262-267.		28
59	Reactive oxygen species: Biological stimuli of neuroblastoma cell response. Cancer Letters, 2005, 228, 111-116.	7.2	27
60	Chemokines in neuroectodermal tumour progression and metastasis. Seminars in Cancer Biology, 2009, 19, 97-102.	9.6	26
61	CCL5-glutamate interaction in central nervous system: Early and acute presynaptic defects in EAE mice. Neuropharmacology, 2013, 75, 337-346.	4.1	25
62	Cytokines in neuroblastoma: from pathogenesis to treatment. Immunotherapy, 2011, 3, 895-907.	2.0	23
63	Close Interactions between Mesenchymal Stem Cells and Neuroblastoma Cell Lines Lead to Tumor Growth Inhibition. PLoS ONE, 2012, 7, e48654.	2.5	23
64	Increase of metaiodobenzylguanidine uptake and intracellular half-life during differentiation of human neuroblastoma cells. , 1996, 67, 95-100.		22
65	Damage-associated molecular patterns (DAMPs) and mesenchymal stem cells: A matter of attraction and excitement. European Journal of Immunology, 2011, 41, 1828-1831.	2.9	22
66	Serum levels of cytoplasmic melanoma-associated antigen at diagnosis may predict clinical relapse in neuroblastoma patients. Cancer Immunology, Immunotherapy, 2011, 60, 1485-1495.	4.2	21
67	Fenretinide as an anti-angiogenic agent in neuroblastoma. Cancer Letters, 2003, 197, 181-184.	7.2	20
68	Biological and clinical role of p73 in neuroblastoma. Cancer Letters, 2003, 197, 111-117.	7.2	19
69	Failure of anti tumor-derived endothelial cell immunotherapy depends on augmentation of tumor hypoxia. Oncotarget, 2014, 5, 10368-10381.	1.8	18
70	MYCN: from oncoprotein to tumor-associated antigen. Frontiers in Oncology, 2012, 2, 174.	2.8	16
71	Metabolic Alterations at the Crossroad of Aging and Oncogenesis. International Review of Cell and Molecular Biology, 2017, 332, 1-42.	3.2	16
72	Effect of starvation on brain glucose metabolism and 18F-2-fluoro-2-deoxyglucose uptake: an experimental in-vivo and ex-vivo study. EJNMMI Research, 2018, 8, 44.	2.5	14

#	ARTICLE	IF	CITATIONS
73	In vitro and In vivo Antitumor Activity of the Novel Derivatized Polyvinyl Alcohol-Based Polymer P10(4). <i>Clinical Cancer Research</i> , 2006, 12, 3485-3493.	7.0	13
74	Role of BAFF in Opsoclonus-Myoclonus syndrome, a bridge between cancer and autoimmunity. <i>Journal of Leukocyte Biology</i> , 2013, 94, 183-191.	3.3	13
75	The role of the P2X7 receptor in myeloid-derived suppressor cells and immunosuppression. <i>Current Opinion in Pharmacology</i> , 2019, 47, 82-89.	3.5	12
76	eATP/P2X7R Axis: An Orchestrated Pathway Triggering Inflammasome Activation in Muscle Diseases. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5963.	4.1	11
77	P2X7 Receptor Antagonist Reduces Fibrosis and Inflammation in a Mouse Model of Alpha-Sarcoglycan Muscular Dystrophy. <i>Pharmaceuticals</i> , 2022, 15, 89.	3.8	11
78	Induction of differentiation and apoptosis by interferon- γ in human neuroblastoma cells in vitro as a dual and alternative early biological response. <i>Cell Death and Differentiation</i> , 1997, 4, 150-158.	11.2	10
79	Unveiling the role of TNF α in mesenchymal stromal cell-mediated immunosuppression. <i>European Journal of Immunology</i> , 2014, 44, 352-356.	2.9	10
80	The Danger Signal Extracellular ATP Is Involved in the Immunomediated Damage of α -Sarcoglycan-Deficient Muscular Dystrophy. <i>American Journal of Pathology</i> , 2019, 189, 354-369.	3.8	9
81	Generation and characterization of dimeric small immunoproteins specific for neuroblastoma associated antigen GD2. <i>International Journal of Molecular Medicine</i> , 2004, 14, 383-8.	4.0	9
82	Comprehensive Phenotyping of Peripheral Blood T Lymphocytes in Healthy Mice. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2021, 99, 243-250.	1.5	8
83	Targeting of <i>PHOX2B</i> expression allows the identification of drugs effective in counteracting neuroblastoma cell growth. <i>Oncotarget</i> , 2017, 8, 72133-72146.	1.8	8
84	Immunosuppressive Treatments in Acute Myocardial Infarction and Stroke. <i>Current Pharmaceutical Biotechnology</i> , 2012, 13, 59-67.	1.6	7
85	Anti Gd2-Immunoliposome-Mediated Targeting of [125I] Metaiodobenzylguanidine to Neuroblastoma and Melanoma Cells in Vitro. <i>Journal of Liposome Research</i> , 1999, 9, 367-385.	3.3	5
86	Targeting of Ubiquitin E3 Ligase RNF5 as a Novel Therapeutic Strategy in Neuroectodermal Tumors. <i>Cancers</i> , 2022, 14, 1802.	3.7	4
87	Disclosing the mysteries of the central nervous system sanctuary for acute lymphoblastic leukemia cells. <i>Leukemia Research</i> , 2011, 35, 699-700.	0.8	3
88	Muscle inflammatory pattern in alpha- and gamma-sarcoglycanopathies. , 2021, 40, 310-318.		3
89	Pancreatic metastasis from mycosis fungoides mimicking primary pancreatic tumor. <i>World Journal of Gastroenterology</i> , 2016, 22, 3496-3501.	3.3	3
90	Potential of crizotinib activity by fasting cycles in an ALK+ lung cancer model.. <i>Journal of Clinical Oncology</i> , 2014, 32, e13511-e13511.	1.6	2

#	ARTICLE	IF	CITATIONS
91	Myeloid-Derived Suppressor Cells and Tumor Growth. , 2014, , 91-109.		2
92	Immunotherapy of neuroblastoma: present, past and future. Expert Review of Neurotherapeutics, 2006, 6, 509-518.	2.8	1
93	Editorial: In-and-out blood vessels: new insights into T cell reverse transmigration. Journal of Leukocyte Biology, 2009, 86, 1271-1273.	3.3	1
94	Immune Adjuvants and Cytokine Therapies. , 2018, , 243-257.		0